drugset
drugset / Trial / NCT07846267

Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma

NCT07846267 ↗

Phase 2 Not yet recruiting 56 enrolled Fudan University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of cryoablation combined with Anlotinib plus TQB2868 in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.

Timeline

Start
2026-10-01
Primary completion
2029-10-01
Completion
2029-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 10 mg Oral
Subject TQB2868 Protein / enzyme biologic 300 mg Intravenous

Indications

intrahepatic cholangiocarcinoma